BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 26951148)

  • 1. Efficacy of Early Postoperative Intraperitoneal Chemotherapy After Complete Surgical Resection of Peritoneal Metastasis from Colorectal Cancer: A Case-Control Study from a Single Center.
    Park SY; Choi GS; Park JS; Kim HJ; Yang CS; Kim JG; Kang BW
    Ann Surg Oncol; 2016 Jul; 23(7):2266-73. PubMed ID: 26951148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P.R.O.P.S. - A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Yong ZZ; Tan GHC; Shannon N; Chia C; Teo MCC
    World J Surg Oncol; 2019 Aug; 17(1):138. PubMed ID: 31391066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin.
    Winer J; Zenati M; Ramalingam L; Jones H; Zureikat A; Holtzman M; Lee K; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2014 May; 21(5):1456-62. PubMed ID: 24201745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Outcomes After R0 Resection of Synchronous Peritoneal Metastasis from Colorectal Cancer Without Cytoreductive Surgery or Hyperthermic Intraperitoneal Chemotherapy.
    Shida D; Tsukamoto S; Ochiai H; Kanemitsu Y
    Ann Surg Oncol; 2018 Jan; 25(1):173-178. PubMed ID: 29063295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does Primary Tumor Side Matter in Patients with Metastatic Colon Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?
    Kelly KJ; Alsayadnasser M; Vaida F; Veerapong J; Baumgartner JM; Patel S; Ahmad S; Barone R; Lowy AM
    Ann Surg Oncol; 2019 May; 26(5):1421-1427. PubMed ID: 30815802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer.
    Lorimier G; Linot B; Paillocher N; Dupoiron D; Verrièle V; Wernert R; Hamy A; Capitain O
    Eur J Surg Oncol; 2017 Jan; 43(1):150-158. PubMed ID: 27839895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer.
    de Cuba EM; de Hingh IH; Sluiter NR; Kwakman R; Coupé VM; Beliën JA; Verwaal VJ; Meijerink WJ; Delis-van Diemen PM; Bonjer HJ; Meijer GA; Te Velde EA
    Ann Surg Oncol; 2016 May; 23(5):1601-8. PubMed ID: 26727921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study.
    Goéré D; Souadka A; Faron M; Cloutier AS; Viana B; Honoré C; Dumont F; Elias D
    Ann Surg Oncol; 2015 Sep; 22(9):2958-64. PubMed ID: 25631064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC.
    Sluiter NR; Rovers KP; Salhi Y; Vlek SL; Coupé VMH; Verheul HMW; Kazemier G; de Hingh IHJT; Tuynman JB
    Ann Surg Oncol; 2018 Aug; 25(8):2347-2356. PubMed ID: 29855834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early postoperative intraperitoneal chemotherapy is associated with survival benefit for appendiceal adenocarcinoma with peritoneal dissemination.
    Huang Y; Alzahrani NA; Liauw W; Soudy H; Alzahrani AM; Morris DL
    Eur J Surg Oncol; 2017 Dec; 43(12):2292-2298. PubMed ID: 29017824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
    Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
    Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.
    McConnell YJ; Mack LA; Francis WP; Ho T; Temple WJ
    J Surg Oncol; 2013 May; 107(6):591-6. PubMed ID: 23129533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of complete cytoreduction with concurrent liver resection followed by hyperthermic intraperitoneal chemotherapy for synchronous peritoneal and liver metastatic colorectal cancer.
    Jeon Y; Park EJ; Lim JH; Baik SH
    World J Surg Oncol; 2019 Dec; 17(1):214. PubMed ID: 31829188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival prognostic factors in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: analysis from a single oncological center.
    Graziosi L; Marino E; De Angelis V; Rebonato A; Donini A
    World J Surg Oncol; 2016 Mar; 14():97. PubMed ID: 27036213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
    Tan GH; Ong WS; Chia CS; Tham CK; Soo KC; Teo MC
    Int J Hyperthermia; 2016 May; 32(3):281-8. PubMed ID: 26862667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.
    Cashin PH; Graf W; Nygren P; Mahteme H
    Eur J Surg Oncol; 2012 Jun; 38(6):509-15. PubMed ID: 22475555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
    Chua TC; Morris DL; Esquivel J
    Ann Surg Oncol; 2010 May; 17(5):1330-6. PubMed ID: 20033321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.